Home » TAKEDA SELECTS LEXICON GENETICS' HYPERTENSION TARGET FOR DEVELOPMENT IN RESEARCH ALLIANCE
TAKEDA SELECTS LEXICON GENETICS' HYPERTENSION TARGET FOR DEVELOPMENT IN RESEARCH ALLIANCE
Lexicon Genetics Incorporated (LEXG) announced that Takeda Pharmaceutical Company Limited has selected LG474 for therapeutic development. LG474 is a target that was discovered by Lexicon in its Genome5000 program.
Therapeutics Daily (http://www.therapeuticsdaily.com/news/article.cfm?contentValue=849469&contentType=sentryarticle&channelID=26)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
07May
-
14May
-
30May